Every material Form 8-K NANOVIRICIDES, INC. has filed with the SEC since July 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
NanoViricides, Inc. extended the employment agreements of its President, Dr. Anil Diwan, and its Chief Financial Officer, Meeta Vyas, both effective July 1, 2026. The filing sets Dr. Diwan's base salary at $400,000 through June 30, 2027, and grants him 10,204 shares of Series A Preferred Stock vesting quarterly through June 30, 2027. The extensions keep the company's two senior executives in place, with the terms disclosed in the filing.
Dr. Anil Diwan extended as President through June 30, 2027, at a base salary of $400,000
Diwan granted 10,204 Series A Preferred Shares, vesting quarterly from September 30, 2026 and fully by June 30, 2027
Diwan severance if terminated without cause: six months' salary; a $2 million term life policy is maintained for him
Meeta Vyas extended as CFO for one year through June 30, 2027; company reimburses up to 50% of health insurance costs, capped at $2,500 per month
NanoViricides closed a registered direct offering on July 27, 2026, selling 2,416,339 common shares at $1.53 each, plus pre-funded warrants and common warrants, for approximately $3.8 million in gross proceeds before placement agent fees and expenses. The company intends to use the net proceeds for working capital, capital expenditures, research and development, clinical trials, and acquisitions and other strategic purposes. The sale adds shares and warrants that could dilute existing shareholders, and the company agreed to register the resale of the warrant shares.
Offering closed July 27, 2026; gross proceeds of approximately $3.8 million, before placement agent fees and offering expenses.
2,416,339 common shares sold at $1.53 per share, plus pre-funded warrants for up to 100,000 shares at $1.52999 per warrant.
Common warrants for up to 2,516,339 shares at $1.75 per share, exercisable six months after issuance and expiring five and one-half years after issuance.
Placement agent D. Boral Capital LLC receives a 7.0% cash fee; the company must file a resale registration statement within 30 days after closing.
NanoViricides, Inc. entered into an at-the-market sales agreement with D. Boral Capital LLC, allowing it to sell common stock from time to time under an existing shelf registration. The filing does not state a dollar amount or number of shares, and sales are not required to occur; the company pays a 2.0% commission on gross proceeds from any sales, which would add shares outstanding and dilute existing holders.
Agreement dated July 17, 2026, with D. Boral Capital LLC as sales agent
Commission of 2.0% of aggregate gross proceeds from each sale
Shares sold under Form S-3 (File No. 333-296550), declared effective June 15, 2026
Sales may be made on the NYSE American or in privately negotiated transactions with company consent
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NANOVIRICIDES, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →